Comparative Pharmacology
Head-to-head clinical analysis: ADLYXIN versus WEGOVY HD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADLYXIN versus WEGOVY HD.
ADLYXIN vs WEGOVY HD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
WEGOVY (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety.
Subcutaneous injection: 10 mcg once daily within 60 minutes before the first meal of the day; may increase to 20 mcg once daily after 2 weeks.
Subcutaneous injection once weekly. Initiate at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg weekly for 4 weeks, then 1 mg weekly for 4 weeks, then 1.7 mg weekly for 4 weeks, then maintain at 2.4 mg weekly.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours after subcutaneous administration, supporting a twice-daily dosing regimen.
Terminal elimination half-life approximately 165 hours (≈7 days), supporting once-weekly dosing.
Renal (predominantly via glomerular filtration and proteolytic degradation; approximately 35% of the dose is excreted unchanged in urine, with the remainder as metabolites and small peptides).
Primarily renal elimination of intact peptide; ~47% excreted unchanged in urine, remainder via fecal/biliary routes (≈38%).
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist